Oxigene underwriters exercise greenshoe for 975,000 shares, raising offering to $27.3 million

By Angela McDaniels

Seattle, Dec. 21 - Oxigene Inc. said that the underwriters of its recent upsized follow-on offering of common stock exercised their 975,000 share over-allotment option in full, raising the off-the-shelf deal to $27,283,750.

Oxigene originally planned to sell 6 million shares at $4.30 each, but priced 6.5 million for $3.65 each on Dec. 15. The company said it now has roughly 28 million shares outstanding.

SG Cowen & Co. LLC was bookrunner for the offering, and Lazard Capital Markets LLC acted as co-lead manager.

Oxigene is a pharmaceutical company based in Waltham, Mass., that develops products to treat cancer and eye diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.